The Societal Burden of Heart Failure With Preserved or Mid-Range Ejection Fraction

Affiliations

¹ Director of Population Health Research, MedStar Health Research Institute, Professor of Medicine, Georgetown University, Washington, DC, USA.
² Assistant Professor of Health Policy and Management, Georgetown University, Washington, DC, USA.

Editorial

William S Weintraub et al. JACC Adv. 2024.

. 2024 Jul 24;3(7):101025.

doi: 10.1016/j.jacadv.2024.101025. eCollection 2024 Jul.

¹ Director of Population Health Research, MedStar Health Research Institute, Professor of Medicine, Georgetown University, Washington, DC, USA.
² Assistant Professor of Health Policy and Management, Georgetown University, Washington, DC, USA.

No abstract available

Keywords: heart failure costs; heart failure mortality; heart failure quality of life.

Conflict of interest statement

Drs Weintraub and Alva have received a grant from Lexicon Pharmaceuticals.

1. Stolfo D., Lund L.H., Benson L., et al. Persistent high burden of heart failure across the ejection fraction spectrum in a Nationwide Setting. J Am Heart Assoc. 2022;11 - PMC - PubMed
1. de Boer A.R., Vaartjes I., Gohar A., et al. Heart failure with preserved, mid-range, and reduced ejection fraction across health care settings: an observational study. ESC Heart Fail. 2022;9:363–372. - PMC - PubMed
1. Sun L.A., Dayer V.W., Hansen R.N., et al. Long-term outcomes of heart failure with preserved or mid-range ejection fraction in the United States. JACC Adv. 2024;3:101027.
1. Anker S.D., Butler J., Filippatos G., et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–1461. - PubMed
1. Solomon S.D., McMurray J.J.V., Anand I.S., et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–1620. - PubMed